P. Kellokumpu-Lehtinen

Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

C. Manegold, Bengt Bergman, A. Chemaissani et al. · Annals of Oncology · 1997 · 114 citations · Full text

Medicine, Oncology, Pharmacology +14

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer

Bengt Bergman, Assad Chemaissani, W. Dornoff et al. · Lung Cancer · 1999 · 72 citations

Medicine, Oncology, Pharmacology +15

Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2

Javier Cortés, José Baselga, P. Kellokumpu-Lehtinen et al. · Journal of Clinical Oncology · 2005 · 39 citations

Medicine, Oncology, Pharmacology +17

Human plasma antioxidant capacity during radiotherapy for lung cancer: a clinical study.

Marina Erhola, M M Nieminen, A Ojala et al. · PubMed · 1998 · 20 citations

Medicine, Oncology, Radiation Oncology +17

Effects of surgical removal of lung cancer on total plasma antioxidant capacity in lung cancer patients.

Marina Erhola, M. M. Nieminen, P. Kellokumpu-Lehtinen et al. · PubMed · 1998 · 18 citations

Life Sciences, Biochemistry, Oncology +15